Table 1.
Brief information of the included studies
| First author | Eriksson S | Oliak D | Tingstedt B | Styrud J | Liu K | Hansson J | Turhan A | Vons C | Hansson J | Mentula P | Salminen P |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Year | 1995 | 2001 | 2002 | 2006 | 2007 | 2009 | 2009 | 2011 | 2012 | 2015 | 2015 |
| Journal | Br J Surg | Dis Colon rectum | Eur J Surg | World J Surg | Am Surg | Br J Surg | Ulus Travma Acil Cerrahi Derg | Lancet | World J Surg | Ann Surg | JAMA |
| Region | Sweden | USA | Sweden | Sweden | USA | Sweden | Turkey | France | Sweden | Finland | Finland |
| Study type | Prospective controlled | Retrospective | Retrospective | Multicentre RCT | Retrospective | Multicentre RCT | Prospective controlled | Multicentre RCT | Prospective nonrandomized | Single centre RCT | Multicentre RCT |
| No. conservative group | 20 | 88 | 50 | 128 | 19 | 202 | 107 | 120 | 442 | 30 | 257 |
| No. surgery group | 20 | 67 | 43 | 124 | 51 | 167 | 183 | 119 | 111 | 30 | 273 |
| Patient type | Mixed | Periappendiceal abscess | Periappendiceal abscess | Mixed | Uncomplicated | Mixed | Mixed | Uncomplicated | Mixed | Periappendiceal abscess | Uncomplicated |
| Antibiotic strategy | (cefotaxime 2 g bid + tinidazole 0.8 g qd) iv 2d + (ofloxacin 0.2 g bid + tinidazole 0.5 g bid) po 8d | iv administration, N/A | (cephalosporin + metronidazole OR imipenem) iv + (cephalosporin + metronidazole) po | (cefotaxime 2 g bid + tinidazole 0.8 g qd) iv 2d + (ofloxacin 0.2 g bid + tinidazole 0.5 g bid) po 10d | iv 1-6d + po 7-14d | (cefotaxime 1 g bid + metronidazole 1.5 g qd) iv 1d + (ciprofloxacin 0.5 g bid + metronidazole 0.4 g tid) po 10d | (ampicillin 1 g qid + gentamicin 160 mg qd + metronidazole 0.5 g tid) iv 3d + N/A po 7d | amoxicillin/clavulanic acid (3 g/d if BW < 90 kg, 4 g/d if BW > 90 kg), iv OR po | (piperacillin/tazobactam 4 g tid) iv 1d + (ciprofloxacin 0.5 g + metronidazole 400 mg bid) po 9d | (cefuroxime 1.5 g tid + metronidazole 0.5 g qd) iv + (cephalexin 0.5 g tid + metronidazole 0.5 g tid) po 7d | (ertapenem 1 g qd) iv 3d + (levofloxacin 0.5 g qd + metronidazole 0.5 g tid) po 7d |
| Other conservative strategy | N/A | PCD selectively, if not improve in 72 h will receive appendectomy | PCD (18%, 9/50) | if not improve in 24 h will receive appendectomy | N/A | N/A | N/A | if not improve in 48 h will receive appendectomy | if not improve in 24–48 h will receive appendectomy | PCD if abscess> 3 cm | N/A |
| Conflict of Interests | Swedish Hoechst AB, Pfizer AB, Mutual Group Life Insurance Company ‘Forenade Liv’ | N/A | N/A | Wallenius Corporation, Aventis Pharma | N/A | None | N/A | None | None | None | Merck, Roche |